A case study of a Freidreich’s ataxia (FA) patient with associated cardiomyopathy reported that an experimental treatment — interferon gamma (INFγ) therapy — could improve cardiac function.
Articles by Kara Elam
Pfizer has published a study with potentially important implications for future therapeutic targets to treat Friedreich’s ataxia (FA). The study,…
Researchers have shown that a potential new therapeutic target for patients with Friedreich’s ataxia (FA) could be a mutation that…
A collaborative team of international researchers led by the Don Carlo Gnocchi Onlus Foundation, in Milan, Italy have shown that…
BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage orphan disease-focused biotechnology company whose mission is to transform excellent science into…
The National Ataxia Foundation (NAF), an organization dedicated to improving the lives of those affected by ataxia through support, education,…